Shire and AbbVie Discuss Possible Deal
New AbbVie proposal results in discussion with Shire about possible $53 billion deal.
In a July 14 statement, Shire reported that the company had requested and received a revised proposal from AbbVie on July 13 for cash and AbbVie shares, with an indicative value of 53.20 British pounds per Shire share, based on share prices of July 11.
Under the revised proposal, Shire shareholders would own approximately 25% of the combined new AbbVie. The new proposal is valued at $53 billion (31 billion pounds) by Reuters.
“The Board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the Revised Proposal to Shire shareholders subject to satisfactory resolution of the other terms of the offer. Accordingly, the Board is in detailed discussions with AbbVie in relation to these terms,” the statement reports.
Shire reports that the revised proposal is subject to the pre-conditions set by AbbVie on July 8, 2014 including due diligence and the recommendation of the Board of Shire and warned that “There can be no certainty that any firm offer will be made.”
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
